|
Cerevel Therapeutics Holdings Inc (NASDAQ: CERE) |
|
Cerevel Therapeutics Holdings Inc
CERE's Fundamental analysis
Select the Comparisons :
|
|
Select the Ratio:
|
|
|
Cerevel Therapeutics Holdings Inc 's sales fell
in the first quarter of 2024 from the same quarter a year ago.
Major Pharmaceutical Preparations industry recorded
growth of revenues by 0.35 %
Cerevel Therapeutics Holdings Inc net loss increased from $-104 millions, to $-132 millions in first quarter of 2024,
• More on CERE's Growth
|
|
Cerevel Therapeutics Holdings Inc realized a net loss in trailing twelve months.
Company is currently trading with Price to Cash flow multiple of 48.98 in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.49.
• More on CERE's Valuation
|
|
|
|
|
Cerevel Therapeutics Holdings Inc realized net loss in trailing twelve months.
Company is currently trading with Price to Cash flow multiple of 48.98 in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.49.
Cerevel Therapeutics Holdings Inc Price to Book Ratio is at 14.47 lower than Industry Avg. of 35.2. and higher than S&P 500 Avg. of 0.01
• More on CERE's Valuation
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com